BIONTECH SE SPON ADS EACH REP 1 ORD SHS
BioNTech SE (BNTX) is a Germany-based biotechnology company known for its mRNA platform and as a co-developer of the Comirnaty COVID-19 vaccine with Pfizer. With a market capitalisation around $25.2 billion, BioNTech combines infectious-disease programmes with an expanding oncology pipeline that includes personalised cancer vaccines and other immunotherapies. Investors should note that the company’s recent revenues were materially bolstered by pandemic vaccine sales, which may be cyclical as public-health demand shifts. BioNTech is R&D intensive, requiring significant spending and clinical progress to unlock long-term value; regulatory approvals, trial outcomes and competition from other vaccine and cancer-therapy developers are key catalysts and risks. Strategic partnerships and manufacturing scale are strengths, but the share price can be volatile. This is general educational information, not investment advice — prospective investors should consider their risk tolerance and seek personalised advice.
Why It's Moving
BioNTech Attracts Analyst Consensus Around 40% Upside as Oncology Pipeline and mRNA Platform Gains Traction
- Analyst consensus has solidified around $130-$136 average price targets, implying approximately 40-48% upside from recent trading levels, with 79% of analysts maintaining Buy or Strong Buy ratings
- Recent regulatory developments, including an advisory panel's decision to ease concerns about mRNA vaccine safety risks, have restored investor confidence in BioNTech's core technology platform and reduced perceived regulatory headwinds
- Oncology pipeline execution has emerged as the primary growth driver offsetting declining COVID-19 vaccine revenues, with analysts viewing the company's late-stage cancer treatment programs as significant long-term value creators despite near-term execution uncertainties
BioNTech Attracts Analyst Consensus Around 40% Upside as Oncology Pipeline and mRNA Platform Gains Traction
- Analyst consensus has solidified around $130-$136 average price targets, implying approximately 40-48% upside from recent trading levels, with 79% of analysts maintaining Buy or Strong Buy ratings
- Recent regulatory developments, including an advisory panel's decision to ease concerns about mRNA vaccine safety risks, have restored investor confidence in BioNTech's core technology platform and reduced perceived regulatory headwinds
- Oncology pipeline execution has emerged as the primary growth driver offsetting declining COVID-19 vaccine revenues, with analysts viewing the company's late-stage cancer treatment programs as significant long-term value creators despite near-term execution uncertainties
When is the next earnings date for BIONTECH SE SPON ADS EACH REP 1 ORD SHS (BNTX)?
BioNTech's next earnings date is May 5, 2026, prior to market open, covering the Q1 2026 financial results. The company will host a conference call at 8:00 a.m. ET to discuss these results and provide a corporate update. This follows their Q4 2025 earnings reported on March 10, 2026.
Stock Performance Snapshot
Analyst Rating
Analysts recommend buying BioNTech's stock with a target price of $141.14, indicating significant growth potential.
Financial Health
BioNTech is generating strong revenue and cash flow, with impressive profit margins from its operations.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Discover More Opportunities
ADAPTIVE BIOTECHNOLOGIES CORP
Adaptive Biotechnologies Corporation is a commercial-stage biotechnology company. The Company is focused on harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its immune medicine platform reveals and translates the massive genetics of the adaptive immune system with scale, precision and speed. It applies its platform to partner with biopharmaceutical companies, inform drug development, and develop clinical diagnostics across its two business segments: Minimal Residual Disease (MRD) and Immune Medicine. The MRD business focuses on the use of its sensitive, next-generation sequencing (NGS) assay to measure MRD in patients with hematologic malignancies. Its MRD business is comprised of its clonoSEQ clinical diagnostic test, offered to clinicians. The IM business focuses on the discovery and development of transformative immune-based therapies in the treatment of patients with cancer and autoimmune diseases.
ABCELLERA BIOLOGICS INC
AbCellera Biologics Inc is a biotechnology company that provides technology to discover and develop novel fully human monoclonal antibodies.
ABSCI CORP
ABSCI Corporation is a biotechnology company focused on the discovery and development of targeted immune modulators for the treatment of cancer and other diseases.
Baskets Featuring BNTX
Beyond Vaccines: The mRNA Revolution
BioNTech's strong vaccine sales are fueling its expansion into new medical fields, particularly cancer treatment. This strategic shift highlights a broader investment opportunity in companies pioneering the next wave of mRNA-based therapies.
Published: August 5, 2025
Explore BasketHypertension Therapy Innovators
This carefully selected group of stocks represents companies at the forefront of developing breakthrough treatments for hypertension, a condition affecting over a billion people worldwide. Following AstraZeneca's groundbreaking trial results, these pharmaceutical innovators are positioned to potentially transform cardiovascular medicine and address a massive unmet medical need.
Published: July 15, 2025
Explore BasketBiotech's IP Moat
This carefully selected group of stocks features biotech companies with powerful patent portfolios. These firms are at the forefront of medical innovation in areas like gene editing and mRNA technology, where intellectual property can create lasting competitive advantages and drive long-term growth.
Published: July 11, 2025
Explore BasketBuffett's Billions: The Philanthropy Effect
Warren Buffett just donated $6 billion to major foundations like the Gates Foundation. This curated list features companies in global health, agriculture, and education that are perfectly positioned to benefit from this massive philanthropic wave.
Published: July 1, 2025
Explore BasketGerman Stocks Soaring
Discover a carefully selected collection of German companies that have been dramatically outperforming their western counterparts. Our team of professional analysts has identified these standout stocks as Germany's economy shows promising signs of growth in 2025.
Published: May 15, 2025
Explore BasketWhy You’ll Want to Watch This Stock
mRNA platform potential
The mRNA approach underpins vaccines and new therapeutics, offering scalability and adaptability, though clinical success and commercial demand can vary.
Oncology pipeline progress
BioNTech’s cancer programmes, including personalised vaccines, could be long-term value drivers if trials succeed, but outcomes and timelines are uncertain.
Partnerships and scale
Collaborations—most notably with Pfizer—boost manufacturing reach and revenue potential, though reliance on partners and market shifts present risks.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
6% Interest on Cash
Earn 6% AER on uninvested cash with daily interest payments.
